Improving effector functions of antibodies for cancer treatment: Enhancing ADCC and CDC

As platforms for therapeutic agents, monoclonal antibodies (MAbs) have already been approved, and several MAbs have demonstrated clinical effectiveness in a variety of malignancies. However, several issues have also been emerging in antibody therapy, such as high cost and insufficient drug action. R...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Natsume, Akito, Niwa, Rinpei, Satoh, Mitsuo
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Dove Medical Press 2009
Konular:
Review
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC2769226/
https://ncbi.nlm.nih.gov/pubmed/19920917
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller